

## Healthcare-Associated & Hospital Acquired Infection and its Infection Control

Adil Raza<sup>1</sup>, Megha Chaudhary<sup>2</sup>

<sup>1</sup>Assistant Professor, Nims University, Nims Paramedical College Jaipur

<sup>2</sup>Assistant Professor, Nims University, Nims Paramedical College Jaipur

### Abstract:

**Background:** Healthcare-associated infections (HCAIs/HAIs) are increasingly driving the outcomes of patients in both acute and long-term care health facilities. Device-associated infections (DAIs) such as ventilator-associated pneumonia (VAP), central line-associated bloodstream infections (CLA-BSIs), catheter-associated urinary tract infections (CA-UTIs) and surgical-site infections (SSIs) together account for most of the HAIs across the world.<sup>[1,2]</sup>

**Objectives:** The prevalence of healthcare-associated & nosocomial infections. Monitoring of hospital-associated infections-by the development of surveillance system. **Prevalence:** Prevention of nosocomial infections requires an integrated, monitored, programme, which includes the following key components-Confining transmission of microorganisms amid patients in direct patient care over adequate hand washing and glove use, and appropriate aseptic practice, isolation strategies, sterilization and disinfection practices, and laundry. Controlling environmental risks for infection. Protecting patients with acknowledge use of prophylactic antimicrobials, nutrition, and vaccinations. Checking the risk of endogenous disease by minimizing invasive procedures and promoting optimal antimicrobial use. Enhancing team patient care practices, and enduring team education. Infection control is the authority of all healthcare experienced - doctors, nurses, therapists, pharmacists, engineers and others.<sup>[49]</sup>

**Conclusion:** Infection control is a never ending struggle as medicine becomes more invasive and the proportion of ageing and immuno-compromised patients in our population continues to increase. Moreover Microbiology laboratory is becoming an integral part of HAI prevention programmes.<sup>[65]</sup> **Keywords:** Hospital Acquired Infection, Control, Microbiology, Healthcare-associated infections , nosocomial infections.

### INTRODUCTION:

Healthcare-associated infections (HCAIs/HAIs) are increasingly driving the outcomes of patients in both acute and long-term care health facilities. Device-associated infections (DAIs) such as ventilator-associated pneumonia (VAP), central line-associated bloodstream infections (CLA-BSIs), catheter-associated urinary tract infections (CA-UTIs) and surgical-site infections (SSIs) together account for most of the HAIs across the world.<sup>[1,2]</sup> HAIs have tremendous implications in terms of associated mortality, morbidity, increased cost of treatment, adverse patient outcomes and social impact. Apart from their escalating rates, HAIs

are now frequently being caused by multi- and pan-drug-resistant organisms, causing therapeutic dilemma. DAIs continue to be one of the main threats to the patient safety, particularly in Intensive Care Units (ICUs) of low- and middle- income countries (LMICs).<sup>[3-6]</sup> Of the annual 12 million deaths, 95% occur in LMICs, where infection prevention and control (IPC) policies are non-existent, poorly adapted or insufficiently funded by governments.<sup>[7,8]</sup>

A growing body of evidence from well-designed studies indicate that up to 10%–70% of HAIs can be prevented by implementation

of appropriate infection control protocols. Most studies support the observations that at least 1/3rd of HAIs can be prevented in HCFs by surveillance and implementation of evidence-based guidelines for prevention of infections (especially device-related infections and SSIs).<sup>[10,11]</sup> Some of the most effective infection prevention measures are the most basic, easy and cost-effective practices that can be incorporated in routine patient care workflows.

Observational studies confirm that evidence-based approaches can reduce infections.<sup>[12,13]</sup>

Antimicrobial resistance (AMR) and the spread of multidrug resistant bacteria is a global patient safety problem and a major public health concern.<sup>[14]</sup> In India, as elsewhere in South East Asia, many interlinked factors—including overuse of antibiotics, limited clinical diagnostic and laboratory capacity, and poor infection control, hygiene, and sanitation—have contributed to the emergence and spread of AMR.<sup>[15-17]</sup> Healthcare facilities are high risk environments for the development and spread of drug resistance<sup>[18-21]</sup> and frequently have the highest burden of multidrug resistant pathogens, such as carbapenem resistant Enterobacteriaceae. Healthcare associated infections thus increase the threat of AMR and contribute to poor patient outcomes.<sup>[22-24]</sup>

The data available indicate that the burden of healthcare associated infections in low and middle income countries like India is high, with an estimated pooled prevalence of 15.5 per 100 patients, more than double the prevalence in Europe and the US.<sup>[25]</sup> Infection prevention and control measures and practices reduce the opportunities for resistant pathogens to spread in healthcare facilities. They are therefore important to efforts to contain AMR.<sup>[26]</sup> At present, however, a lack

of adequate systems and infrastructure for infection prevention and control in many healthcare facilities contributes to the development of healthcare associated infections and the spread of resistant pathogens.<sup>[23,27]</sup>

In India, accurate estimates of the burden of healthcare associated infections are limited by the absence of reliable and routine standardised surveillance data. Published reports of healthcare associated infections are mostly from individual health facilities and include short term prospective studies and point prevalence surveys conducted in selected patient units of large hospitals.<sup>[28-32]</sup>

These indicate a prevalence of healthcare associated infections ranging from 7 to 18 per 100 patients, which is similar to that reported from other low and middle income countries. As in other settings, healthcare associated infections in India are associated with longer hospital stays, increased mortality, and added costs.<sup>[29,30,32]</sup>

The frequent use of indwelling devices is also reported, particularly in intensive care units, where one centre reported that over 70% of patients had indwelling devices in its intensive care unit for more than 48 hours.<sup>[29]</sup> While microbiological confirmation of the healthcare associated infections was not a requirement in each of these reports, the data indicate that many of these infections were due to multidrug resistant pathogens, including meticillin resistant *Staphylococcus aureus* (MRSA) and extended spectrum  $\beta$ -lactamase producing and carbapenem resistant Enterobacteriaceae, *Pseudomonas* spp, and *Acinetobacter* spp.<sup>[29,30]</sup> However, the results reported are not comparable across studies or sites in India as the healthcare facilities did not necessarily use standardised case definitions and surveillance methods

### CAUSATIVE ORGANISMS:

Around 12–17 microorganisms cause 80%–87% of HCAs: *S. aureus*, *Enterococcus species* (eg, *faecalis*, *faecium*), *E. coli*, coagulase-negative *Staphylococci*, *Candida species* (eg, *albicans*, *glabrata*), *K. pneumoniae* and *Klebsiella oxytoca*, *P. aeruginosa*, *A. baumannii*, *Enterobacter species*, *Proteus species*, Yeast NOS, *Bacteroides species*, and other pathogens.<sup>[33,34,35]</sup> Among these pathogens, 16%–20% include multidrug-resistant (MDR) phenotypes: MRSA, vancomycin-resistant *E. faecium*, carbapenem-resistant *P. aeruginosa*, extended-spectrum cephalosporin-resistant *K. pneumoniae*, *K. oxytoca*, *E. coli*, and *Enterobacter species*, and carbapenem-resistant *P. aeruginosa*, *K. pneumoniae*/ *K. oxytoca*, *E. coli*, *Enterobacter species*, and *A. baumannii*.<sup>[33,34]</sup> Some of these Gram-negative microorganisms have a much higher rate (20%–40%) of resistance than others<sup>[33]</sup> with the organisms isolated from device-associated HCAs having the highest antimicrobial resistance phenotypes.<sup>[35]</sup> In the latter study, although similar to the percentage resistance for most phenotypes was that in an earlier research study,<sup>[33]</sup> an upsurge in the scale of the resistance fractions against *E. coli* pathogens was observed, especially with fluoroquinolones.<sup>[35]</sup> *Acinetobacter*, *Burkholderia spp.* and *Pseudomonas spp.* isolates were 100% were 92% resistant to cephalosporins respectively. *Burkholderia spp.*

### ROUTES OF TRANSMISSION

Microorganisms are transmitted in hospitals by **direct contact**: This requires mechanical transfer of pathogens between patients through a health care worker or a medical kit.

Microorganisms are transmitted in hospitals by **indirect contact**: This requires mechanical transfer of pathogens between patients through a health care worker or a medical kit.

#### 1. Contact route

There are two types of contact routes:

**Direct Contact**: It requires physical contact between the infectious individual or contaminated object and the susceptible host.

was again totally resistant to fluoroquinolones and *Acinetobacter spp.* and *Pseudomonas spp.* were 94.2% and 95.8% resistant, respectively. The same study reported that 86.4% *Acinetobacter spp.* and 62.5% *Pseudomonas spp.* showed a high resistance to carbapenems, the preferred drug regime in ICUs. Carbapenems were found more effective against *Burkholderia spp.* with 20% resistance.<sup>[36]</sup> In another study, *Enterobacteriaceae* community were found to be completely resistant to third-generation cephalosporins.<sup>[36]</sup>

Over 80% of the *Klebsiella spp.* community were resistant to ciprofloxacin, gentamicin, piperacillin, tazobactam, and imipenem showing 48.6% resistance. *E. coli* was equally resistant although carbapenems were effective in almost 80% cases. Although *Citrobacter spp.* related HCAs are a relatively minor proportion, they also show resistance toward cephalosporins, fluoroquinolones, and aminoglycosides.<sup>[37]</sup> Another study reported that although the *Acinetobacter spp.* were 76.99%–92.01%, resistant to most antimicrobials, only 30% of *Acinetobacter spp.* isolated were susceptible.<sup>[38]</sup> It can be seen therefore that the causative pathogenic microorganisms differ from country to country as does patterns of resistance

**2. Air borne route**  
Airborne transmission occurs by dissemination of either airborne droplet nuclei (small particle residue 5 microns or smaller in size of evaporated droplet containing microorganisms that remain suspended in the air for long periods of time)

or dust particles containing infectious agent.<sup>[40]</sup> Microorganisms carried in this manner can be dispersed widely by air current and may become inhaled by a susceptible host within the same room or over a long distance from the source patient depending on environmental factors. Examples include Mycobacterium tuberculosis, Legionella, and the Rubeola and Varicella viruses.

### **3. Droplet route**

Droplet particles, produced by coughing, sneezing and even talking, can settle either

on surrounding surfaces or on the body mucosa which can be transferred to others. Examples include meningitis and pneumonia.

### **4. Common vehicle transmission**

It applies to microorganisms transmitted to the host by contaminated items such as food, water, medications, devices and equipments.

### **5. Vector borne transmission**

It occurs when vectors such as mosquitoes, flies, rats and other vermin transmit microorganisms.<sup>[39,41,42]</sup>

## **DIFFERENT TYPES OF INFECTIONS ACQUIRED IN HOSPITALS INCLUDE**

Bloodstream infections, ventilator-associated pneumonia, Urinary Tract Infection (UTI), lower respiratory infection, gastrointestinal, skin, soft tissue, surgical-site infections, ear, nose, and throat infections.<sup>[41]</sup>

## **HIGH-RISK SITUATIONS FOR ACQUIRING HOSPITAL-ACQUIRED INFECTIONS**

There are numerous risk factors which predispose a host to acquire HAIs including low body resistance as in infancy and old age, serious underlying illnesses, major surgeries,<sup>[42]</sup> immune deficiency states<sup>[44]</sup> and prolonged hospital stay.<sup>[45]</sup> There are areas in the hospital which carry a greater risk of patients acquiring HAI's<sup>[46,47]</sup> These include intensive care unit, dialysis unit, organ transplant unit, burns unit, operation theatres, delivery rooms, post-operative wards.

## **PREVENTION<sup>[49]</sup>**

Prevention of nosocomial infections requires an integrated, monitored, programme, which includes the following key components-

Limiting transmission of organisms between patients in direct patient care through adequate hand washing and glove use, and appropriate aseptic practice, isolation strategies, sterilization and disinfection practices, and laundry

Controlling environmental risks for infection

Protecting patients with appropriate use of prophylactic antimicrobials, nutrition, and vaccinations

Limiting the risk of endogenous infections by minimizing invasive procedures and promoting optimal antimicrobial use

Surveillance of infections, identifying and controlling outbreaks

Prevention of infection in staff members

Enhancing staff patient care practices, and continuing staff education. Infection control is the responsibility of all healthcare professionals - doctors, nurses, therapists, pharmacists, engineers and others

## HOSPITAL INFECTION CONTROL PROGRAMME

“The first requirement of a hospital is that it should do the sick no harm” was Florence Nightingale’s dictum. Each healthcare facility needs to develop an infection control programme to ensure the well being of both patients and staff.<sup>[45]</sup>

It also needs to work on developing an annual work plan to assess and promote good health care, and provide sufficient resources to support the infection control programme.

Infection prevention and control programmes were initially implemented in hospitals in the US in the 1960s, but it was not until the publication of the Study on the Efficacy of Nosocomial Infection Control (SENIC) in 1985 that the best evidence of their efficacy in reducing HAIs became available.<sup>[50]</sup> This study showed that hospitals with an infection control programme that included surveillance and control components were able to reduce HAIs by 32% compared with those hospitals that did not have this type of programme or the critical components.<sup>[51]</sup>

## ROLE OF THE MICROBIOLOGY LABORATORY<sup>[53,54,55,56]</sup>

The microbiology laboratory has a pivotal role in the control of hospital associated infections. The clinical microbiology laboratory is an essential component of an effective infection control program. The microbiology laboratory should be involved in all aspects of the infection control program. Particularly important are its roles in the hospital's infection surveillance system and in assisting the infection control program to effectively and efficiently use laboratory services for epidemiologic purposes.<sup>[54]</sup> Clinical microbiology laboratory plays a pivotal role in patient care providing information on a variety of microorganisms with clinical significance and is an essential component of an effective infection control program.<sup>[57]</sup> The microbiologist is usually the infection control officer.

The infection control and prevention programme at the hospital is a planned, systematic approach to monitor and evaluate the quality and appropriateness of infection control procedures and practices. The programme is a plan of action which is designated to identify infections that occur in patients and staff that have the potential for disease transmission, identify opportunities for the reduction of risk for disease transmission, recommend risk reduction practices by integrating principles of sound infection control management into patient care, education and training of employees, sterilisation and disinfection practices at the hospital and manage surveillance through internal audits and various reporting tools.

The main aim of the infection control programme is to lower the risk of an infection during the period of hospitalization. Hospital infection control programs can prevent 33% of nosocomial infections.<sup>[52]</sup>

The role of the department in the HAI control programme includes:

Identification of pathogens - the laboratory should be capable of identifying the common bacteria to the species level. Provision of advice on antimicrobial therapy. Provision of advice on specimen collection and transport. Provision of information on antimicrobial susceptibility of common pathogens.<sup>[58]</sup> On basis of periodic summaries of laboratory data and data on antibiotic consumption, the microbiologist can keep the clinicians informed about antibiotic resistance and compliance with the antibiotic guidelines. Periodic reporting of hospital infection data and antimicrobial resistance pattern - The periodic reporting of such date is an important service provided by the microbiology department. The frequency of this should be as determined by the ICC.<sup>[59]</sup>



Identification of sources and mode of transmission of infection - Culture of carriers, environment for identifying the source of the organism causing infection (outbreak organism).<sup>[60]</sup> The selection of sites for culture depends upon the known epidemiology and survival characteristics of the organism. Epidemiological typing of the isolates from cases, carriers and environment.

Microbiological testing of hospital personnel or environment.<sup>[61]</sup> Testing for potential carriers of epidemiologically significant organisms. As a part of the infection control programme, the microbiology laboratory at times may need to culture potential environmental and personnel sources of nosocomial infections. Usually this is limited to outbreak situation when the source and method of transmission needs to be identified. Routine microbiological sampling and testing is not recommended<sup>[62]</sup> Providing support for sterilization and disinfection in the facility including biological monitoring of sterilization.

The training programme should include the following:

Basic concepts of infection. Hazards associated with their particular category of work;

### CONCLUSION:

Infection control is a never ending struggle as medicine becomes more invasive and the proportion of ageing and immuno-compromised patients in our population continues to increase. Hospitals should come up with an in-house awareness programme where staff members, patients and their relatives can be educated on maintaining

**KEYWORDS:** Hospital Acquired Infection, infections, nosocomial infections.

### REFERENCES:

Providing facilities for microbiological testing of hospital materials when considered necessary.<sup>[63]</sup> These may include: sampling of infant feeds; monitoring of blood products and dialysis fluids; quality control sampling of disinfected equipment; Additional sterility testing of commercially sterilized equipment is not recommended

Providing training for personnel involved in infection control<sup>[64]</sup> - This forms an important part of the Infection Control Programme. Each hospital should develop an employee training programme. The aim of the training programme is to thoroughly orient all hospital personnel to the nature of HAI and to ways of prevention and treatment. As the various hospital employees have different functions and their level of education is different, the training programme needs to be altered to suit the functional requirements of each category of staff and should be adapted accordingly.

Acceptance of their personal responsibility and role in the control of hospital infection;. Methods to prevent the transmission of infection in the hospital. Safe work practice.

hygiene. Moreover Microbiology laboratory is becoming an integral part of HAI prevention programmes. The emergence of new pathogens, and new resistances in old pathogens, makes microbiology laboratory indispensable for successful prevention of HAI, not only outbreaks, but sporadic cases too.<sup>[65]</sup>

Control, Microbiology, Healthcare-associated

1. Durlach R, McIlvenny G, Newcombe RG, Reid G, Doherty L, Freuler C, *et al.* Prevalence survey of healthcare-associated infections in Argentina; comparison with England, Wales, Northern Ireland and South Africa. *J Hosp Infect* 2012;80:217-23.
2. Raffaldi I, Scolfaro C, Pinon M, Garazzino S, Dalmasso P, Calitri C, *et al.* Surveillance study of healthcare-associated infections in a pediatric neurosurgery unit in Italy. *Pediatr Neurosurg* 2011;47:261-5.
3. Kollef MH. Prevention of ventilator-associated pneumonia or ventilator-associated complications: A worthy, yet challenging, goal. *Crit Care Med* 2012;40:271-7.
4. Rosenthal VD, Maki DG, Salomao R, Moreno CA, Mehta Y, Higuera F, *et al.* Device-associated nosocomial infections in 55 Intensive Care Units of 8 developing countries. *Ann Intern Med* 2006;145:582-91.
5. Salgado Yopez E, Bovera MM, Rosenthal VD, González Flores HA, Pazmiño L, Valencia F. Device-associated infection rates, mortality, length of stay and bacterial resistance in Intensive Care Units in Ecuador: International Nosocomial Infection Control Consortium's findings. *World J Biol Chem* 2017;8:95-101.
6. Mathur P, Tak V, Gunjyal J, Nair SA, Lalwani S, Kumar S, *et al.* Device-associated infections at a level-1 trauma centre of a developing nation: Impact of automated surveillance, training and feedbacks. *Indian J Med Microbiol* 2015;33:51-62.
7. Pittet D, Allegranzi B, Storr J, Bagheri Nejad S, Dziekan G, Leotsakos A, *et al.* Infection control as a major World Health Organization priority for developing countries. *J Hosp Infect* 2008;68:285-92.
8. McFee RB. Nosocomial or hospital-acquired infections: An overview. *Dis Mon* 2009;55:422-38.
9. Allegranzi B, Pittet D. Healthcare-associated infection in developing countries: Simple solutions to meet complex challenges. *Infect Control Hosp Epidemiol* 2007;28:1323-7.
10. Haley RW, Quade D, Freeman HE, Bennett JV. The SENIC project. Study on the efficacy of nosocomial infection control (SENIC project). Summary of study design. *Am J Epidemiol* 1980;111:472-85.
11. Harbarth S, Sax H, Gastmeier P. The preventable proportion of nosocomial infections: An overview of published reports. *J Hosp Infect* 2003;54:258-66.
12. Zilberberg MD, Shorr AF, Kollef MH. Implementing quality improvements in the Intensive Care Unit: Ventilator bundle as an example. *Am J Infect Control* 2009;37:172-5.
13. Jeffries HE, Mason W, Brewer M, Oakes KL, Muñoz EI, Gornick W, *et al.* Prevention of central venous catheter-associated bloodstream infections in pediatric Intensive Care Units: A performance improvement collaborative. *Infect Control Hosp Epidemiol* 2009;30:645-51.
14. Laxminarayan R, Duse A, Wattal C, *et al.* Antibiotic resistance—the need for global solutions. *Lancet Infect Dis* 2013;13:1057-98. doi:10.1016/S1473-3099(13)70318-9
15. Holmes AH, Moore LS, Sundsfjord A, *et al.* Understanding the mechanisms and drivers of antimicrobial resistance.

- Lancet* 2016;387:176-87. doi:10.1016/S0140-6736(15)00473-0
16. Laxminarayan R, Heymann DL. Challenges of drug resistance in the developing world. *BMJ* 2012;344:e1567. doi:10.1136/bmj.e1567
17. Morgan DJ, Okeke IN, Laxminarayan R, Perencevich EN, Weisenberg S. Non-prescription antimicrobial use worldwide: a systematic review. *Lancet Infect Dis* 2011;11:692-701. doi:10.1016/S1473-3099(11)70054-8
18. Cardoso T, Almeida M, Carratalà J, et al. Microbiology of healthcare-associated infections and the definition accuracy to predict infection by potentially drug resistant pathogens: a systematic review. *BMC Infect Dis* 2015;15:565. doi:10.1186/s12879-015-1304-2
19. Mehrad B, Clark NM, Zhanel GG, Lynch JP3rd. Antimicrobial resistance in hospital-acquired gramnegative bacterial infections. *Chest* 2015;147: 1413-21. doi:10.1378/chest.14-2171
20. Weiner LM, Webb AK, Limbago B, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011- 2014. *Infect Control Hosp Epidemiol* 2016;37:1288-301. doi:10.1017/ice.2016.174
21. Pitout JD, Nordmann P, Poirel L. Carbapenemase-producing *Klebsiella pneumoniae*, a key pathogen set for global nosocomial dominance. *Antimicrob Agents Chemother* 2015;59:5873-84. doi:10.1128/AAC.01019-15
22. Zimlichman E, Henderson D, Tamir O, et al. Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system. *JAMA Intern Med* 2013;173:2039-46. doi:10.1001/jamainternmed.2013.9763
23. Zaidi AK, Huskins WC, Thaver D, Bhutta ZA, Abbas Z, Goldmann DA. Hospital-acquired neonatal infections in developing countries. *Lancet* 2005;365:1175-88. doi:10.1016/S0140-6736(05)71881-X
24. Umscheid CA, Mitchell MD, Doshi JA, Agarwal R, Williams K, Brennan PJ. Estimating the proportion of healthcare-associated infections that are reasonably preventable and the related mortality and costs. *Infect Control Hosp Epidemiol* 2011;32:101-14. doi:10.1086/657912
25. Allegranzi B, Pittet D. Healthcare-associated infection in developing countries: simple solutions to meet complex challenges. *Infect Control Hosp Epidemiol* 2007;28:1323-7. doi:10.1086/521656
26. The Review on Antimicrobial Resistance. Infection prevention, control and surveillance: limiting the development and spread of drug resistance. 2016. [https://amr-review.org/sites/default/files/Health%20infrastructure%20and%20surveillance%20final%20version\\_LR\\_NO%20CROPS.pdf](https://amr-review.org/sites/default/files/Health%20infrastructure%20and%20surveillance%20final%20version_LR_NO%20CROPS.pdf).
27. Weiner LM, Fridkin SK, Aponte-Torres Z, et al. Vital signs: preventing antibiotic-resistant infections in hospitals - United States, 2014. *MMWR Morb Mortal Wkly Rep* 2016;65:235-41. doi:10.15585/mmwr.mm6509e1
28. Kamath S, Mallaya S, Shenoy S. Nosocomial infections in neonatal intensive care units: profile, risk factor assessment and antibiogram. *Indian J Pediatr* 2010;77:37-9. doi:10.1007/s12098-010-0005-5



29. Gupta A, Kapil A, Lodha R, et al. Burden of healthcare-associated infections in a paediatric intensive care unit of a developing country: a single centre experience using active surveillance. *J Hosp Infect* 2011;78:323-6. doi:10.1016/j.jhin.2011.04.015
30. Kumar A, Biswal M, Dhaliwal N, et al. Point prevalence surveys of healthcare-associated infections and use of indwelling devices and antimicrobials over three years in a tertiary care hospital in India. *J Hosp Infect* 2014;86:272-4. doi:10.1016/j.jhin.2013.12.010
31. Singh AK, Jain S, Kumar D, Singh RP, Bhatt H. Antimicrobial susceptibility pattern of extended spectrum beta-lactamase producing *Klebsiella pneumoniae* clinical isolates in an Indian tertiary hospital. *J Res Pharm Pract* 2015;4:153-9. doi:10.4103/2279-042X.162363
32. Sodhi J, Satpathy S, Sharma DK, et al. Healthcare associated infections in paediatric intensive care unit of a tertiary care hospital in India: hospital stay & extra costs. *Indian J Med Res* 2016;143:502-6. doi:10.4103/0971-5916.184306
33. Sievert DM, Ricks P, Edwards JR, et al; National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. *Infect Control Hosp Epidemiol*. 2013;34(1):1-14
34. Hidron AI, Edwards JR, Patel J, et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. *Infect Control Hosp Epidemiol*. 2008;29(11): 996-1011.
35. Weiner LM, Webb AK, Limbago B, et al. Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014. *Infect Control Hosp Epidemiol*. 2016;37(11):1288-1301.
36. Messina AF, Berman DM, Ghazarian SR, et al. The management and outcome of spinal implant-related infections in pediatric patients: a retrospective review. *Pediatr Infect Dis J*. 2014;33(7):720-723.
37. Parajuli NP, Acharya SP, Mishra SK, Parajuli K, Rijal BP, Pokhrel BM. High burden of antimicrobial resistance among gram negative bacteria causing healthcare associated infections in a critical care unit of Nepal. *Antimicrob Resist Infect Control*. 2017;6(1):67
38. Banerjee T, Mishra A, Das A, Sharma S, Barman H, Yadav G. High Prevalence and Endemicity of Multidrug Resistant *Acinetobacter* spp. in Intensive Care Unit of a Tertiary Care Hospital, Varanasi, India. *J Pathog*. 2018;2018(2):9129083.
39. Prevention of hospital-acquired infections. A practical guide 2nd edition. World Health Organization Department of Communicable Disease, Surveillance and Response. 2002. Available at: <http://www.who.int/csr/resources/publications/whocdscsreph200212.pdf>.

40. Nosocomial infections and infection control in hospital. 2007. Available at: [http://complab.nymc.edu/Curriculum/ComPrevMed/Nosocomial Infections.htm](http://complab.nymc.edu/Curriculum/ComPrevMed/Nosocomial%20Infections.htm).
41. Weinstein RA. Nosocomial infection update. *Emerg. Infect. Dis.* 1998;4(3):416-20.
42. Bonten MJ, Hayden MK, Nathan C, van Voorhis J, Matushek M, Slaughter S, Rice T, Weinstein RA. Epidemiology of colonisation of patients and environment with vancomycin-resistant enterococci. *Lancet.* 1996 Dec;348(9042):1615-9.
43. Dunn DL. Hazardous crossing: immunosuppression and nosocomial infections in solid organ transplant recipients. *Surg Infect.* 2001;2:103-10.
44. Practical guidelines for infection control in health care facilities. 2002. Available at: <http://www.who.int/>.
45. McNicholas, S., Andrews, C., Boland, K., Shields, M., Doherty, G.A., Murray, F.E., Smith, E.G., Humphreys, H., & Fitzpatrick, F. Delayed acute
46. hospital discharge and healthcare-associated infections: the forgotten risk factors. *J Hosp Infect.* 2011;78:157-8.
47. Mayon-White RT, Dual G, Kereselidze T, Tikhomirov E. An international survey of the prevalence of hospital acquired infection. *J Hosp Infect.* 1988;11:S43-8.
48. Britt MR, Burk JP, Nordquist AG et al. Infection control in small hospital: prevalence surveys in 18 institutions. *JAMA.* 1976;236:1700-3.
49. Prevention of hospital-acquired infections" in health care facilities. 2003. Available at: <http://www.who.int/emc>
50. Nosocomial infection. 2009. Available at: [http://en.wikipedia.org/wiki/nosocomial\\_infection](http://en.wikipedia.org/wiki/nosocomial_infection). Accessed June 2009.
51. The SENIC Project. Study on the efficacy of nosocomial infection control (SENIC Project). Summary of study design. Haley RW, Quade D, Freeman HE, Bennett JV *Am J Epidemiol.* 1980 May;111(5):472-85.
52. Horan T.C, Gaynes R.P. Surveillance of nosocomial infections. In: Mayhall C.G eds. *Williams and Wilkins Hospital epidemiology and infection control* 3rd ed. Philadelphia: Lippincott; 2004: 1659-1702.
53. Prevention of hospital-acquired infections. A practical guide 2nd edition. World Health Organization Department of Communicable Disease, Surveillance and Response. 2002. Available at: <http://www.who.int/csr/resources/publications/whocdscsreph200212.pdf>.
54. Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. *Clin Microbiol Rev.* 1993;6:428-42.
55. Guidelines on Prevention and Control of Hospital Associated Infections World Health Organization Regional Office for South-East Asia SEA-HLM-343. 2002. Available at: [http://apps.searo.who.int/PDS\\_DOCS/B0007.pdf](http://apps.searo.who.int/PDS_DOCS/B0007.pdf). Accessed January 2002.
56. Wiblin RT, Wenzel RP. The infection Control Committee *Infect Control Hosp Epidemiol.* 1996;17:44-46
57. Kalenic S, Budimir A. The role of microbiology laboratory in healthcare-associated infection prevention. *Int J Infect Control.* 2009;5:i2.
58. Kolmos HJ. Interaction between the microbiology laboratory and clinician: what the microbiologist can provide. *J Hosp Infect.* 1999 Dec;43Suppl:S285-91.
59. Michael A. Pfaller and Loreen A. Herwaldt. *The Clinical Microbiology*

- Laboratory and Infection Control: Emerging Pathogens, Antimicrobial Resistance, and New Technology Clinical Microbiology Laboratory and Infection Control. 1997;25:858-70.
60. Laboratory role in the management of hospital acquired infections Wilson MP, Spencer RC. J Hosp Infect. 1999 May;42(1):1-6.
61. Mallison, G. F., and R. W. Haley. Microbiologic sampling of the inanimate environment in U.S. hospitals. Am. J. Med. 1981;70:941-76.
62. Centers for Disease Control. Guideline for handwashing and hospital environmental control. Infect. 1985;7:231-42.
63. T. Grace Emori and Robert P. Gaynes. An Overview of Nosocomial Infections, Including the Role of the Microbiology Laboratory. Clinical Microbiology Reviews. 1993 Oct;6(4):428-42.
64. L. Barth Reller, Melvin P. Weinstein et al. Role of Clinical Microbiology Laboratories in the Management and Control of Infectious Diseases and the Delivery of Health Care. Clin Infect Dis. 2001;32(4): 605-10.
65. Asifa Nazir, S. M. Kadri. An overview of hospital acquired infections and the role of the microbiology laboratory. International Journal of Research in Medical Sciences | January-March 2014 | Vol 2 | Issue 1 Page 21 DOI: 10.5455/2320-6012.ijrms20140205